Gene therapy to treat cardiac arrhythmias.
Gene therapy to treat electrical dysfunction of the heart is an appealing strategy because of the limited therapeutic options available to manage the most-severe cardiac arrhythmias, such as ventricular tachycardia, ventricular fibrillation, and asystole. However, cardiac genetic manipulation is challenging, given the complex mechanisms underlying arrhythmias. Nevertheless, the growing understanding of the molecular basis of these diseases, and the development of sophisticated vectors and delivery strategies, are providing researchers with adequate means to target specific genes and pathways involved in disorders of heart rhythm. Data from preclinical studies have demonstrated that gene therapy can be successfully used to modify the arrhythmogenic substrate and prevent life-threatening arrhythmias. Therefore, gene therapy might plausibly become a treatment option for patients with difficult-to-manage acquired arrhythmias and for those with inherited arrhythmias. In this Review, we summarize the preclinical studies into gene therapy for acquired and inherited arrhythmias of the atria or ventricles. We also provide an overview of the technical advances in the design of constructs and viral vectors to increase the efficiency and safety of gene therapy and to improve selective delivery to target organs.
Division of Cardiology and Molecular Cardiology, Fondazione Salvatore Maugeri, Via Maugeri 10/10°, 27100 Pavia, Italy.
Rossana
R
Bongianino
Division of Cardiology and Molecular Cardiology, Fondazione Salvatore Maugeri, Via Maugeri 10/10°, 27100 Pavia, Italy.
Silvia G
SG
Priori
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans